John, Mike & Tom's <b>Wild World of Stocks</b> Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: wlheatmoon who wrote (1178)	6/1/2000 6:42:00 PM
From: John Pitera	Read Replies (2) of 2850

the ideal thing would be to be able to detect early cancer and metastatic recurrence before clinical evidence does it appear they can do that? what would they have to do. wow they were up 70% today. I never got out of the last thousand, and I've still got some of this in my PA..... it's a real black hole things get in there and never get out..... -g- ------------ I just see the 8 million women taking progestin and estrogen have a much greater chance of getting breast cancer Hormone therapy found to boost risk of breast cancer June 1, 2000 Web posted at: 11:26 AM EDT (1526 GMT) SEATTLE (AP) -- Use of a hormone-replacement therapy with estrogen and progestin can more than double the risk of a form of breast cancer, researchers reported today in the journal Cancer. Scientists at the Fred Hutchinson Cancer Research Center studied 537 King County women at least 50 years old who had breast cancer from 1988 to 1990. They were compared with 492 women who had not had the disease. Scientists found a 2.6-fold higher incidence of lobular breast cancer in women who took the combination therapy for at least six months and an average of four years. The reason only one form of cancer increased is "a question for the future: Do some women have certain characteristics that make them more susceptible to lobular cancer when using replacement therapy?" said Dr. Christopher Li, the study's lead author. About 85 percent of invasive breast cancer cases are in the ducts that carry milk to the nipple. Lobular cancer occurs in the milk-producing lobules and affects about 10 percent of breast-cancer cases. About 8.6 million women in the United States take the combination therapy treatment and 12 million take estrogen alone. The hormones reduce the risk of broken bones from osteoporosis and ease menopausal symptoms. In women who have not had a hysterectomy, progestin is used to lower the risk of endometrial cancer. Earlier studies, including two this year, indicated a heightened risk of breast cancer among women using combination hormone therapy for at least five years but not among those using estrogen alone. In a related study, Li found a 35 percent increase in lobular cancer between 1988 and 1995. "Although preliminary, our studies suggest that the incidence of lobular breast cancer is increasing nationwide and that the use of postmenopausal hormone replacement therapy, specifically the use of combined estrogen plus progestin preparations, may be contributing to this increase," Li said. He said more studies were required to confirm the findings.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next